Target intelligence / Profile preview

Invasion plasmid antigen proteins (Ipa)

Target
Ipa
Molecular classification
Bacterial effector protein, Type III secretion system component, Virulence factor, Translocon protein
01

Overview

Invasion plasmid antigen (Ipa) proteins are critical virulence factors produced by Shigella sonnei, encoded on a large 220-kb virulence plasmid (Schroeder & Hilbi, 2008). These proteins, including IpaA, IpaB, IpaC, and IpaD, are essential components of the Type III secretion system (T3SS), which functions as a molecular syringe to deliver effectors into host cells (Picking et al., 2005). IpaB and IpaC specifically form the translocon pore in the host cell membrane, enabling bacterial invasion and escape from the phagosome (Blocker et al., 1999). IpaD acts as a scaffold and regulator for the needle tip, controlling the secretion of other effectors (Picking et al., 2005). Due to their high conservation across Shigella species and their indispensable role in pathogenesis, they are major targets for vaccine development, such as the Invaplex complex (Turbyfill et al., 2000). Therapeutic approaches aim to generate neutralizing antibodies that block the T3SS assembly or function, thereby preventing the onset of bacillary dysentery. Research into small molecule inhibitors of the T3SS also targets the interaction between these proteins to disrupt the infection cycle (Barta et al., 2012). These antigens are highly immunogenic, making them ideal candidates for diagnostic and protective applications.

Other names
Ipa proteinsInvasion plasmid antigensIpaAIpaBIpaCIpaDVirulence plasmid antigensInvaplex componentsShigella sonnei invasion plasmid antigens
02

Mechanism of action

Inhibition of Type III secretion system (T3SS) mediated host cell invasion via antibody-mediated neutralization or structural disruption of the translocon pore (Turbyfill et al., 2000; Schroeder & Hilbi, 2008).

03

Biological functions

Bacterial invasionHost cell membrane disruptionPhagosomal escapeCytoskeleton rearrangementInduction of apoptosisType III secretion system regulation
04

Disease associations

InfectionShigellosisBacillary dysentery
05

Safety considerations

Reactogenicity of live-attenuated vaccine platformsInflammatory response to bacterial antigensRequirement for high mucosal antibody levels for efficacy
06

Interacting drugs

Invaplex (vaccine candidate)

3 more in the full profile.

07

Biomarkers

Serum anti-IpaB IgG titersSerum anti-IpaC IgG titersSerum anti-IpaD IgG titersFecal anti-Ipa IgA levels

Beyond the preview

Go deeper on Invasion plasmid antigen proteins (Ipa).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Invasion plasmid antigen proteins (Ipa).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call